Dongkuk Pharmaceuticals herbal medicine gum drug Insadol will enter the European market in earnest .. - MK -
086450 Stock | KRW 16,640 40.00 0.24% |
About 62% of DongKook Pharmaceutical's investor base is looking to short. The analysis of current outlook of investing in DongKook Pharmaceutical Co suggests that many traders are alarmed regarding DongKook Pharmaceutical's prospects. The current market sentiment, together with DongKook Pharmaceutical's historical and current headlines, can help investors time the market. In addition, many technical investors use DongKook Pharmaceutical stock news signals to limit their universe of possible portfolio assets.
DongKook |
Dongkuk Pharmaceuticals herbal medicine gum drug Insadol will enter the European market in earnest .. - MK
Read at news.google.com
DongKook Pharmaceutical Fundamental Analysis
We analyze DongKook Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DongKook Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DongKook Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
DongKook Pharmaceutical is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
DongKook Pharmaceutical Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with DongKook Pharmaceutical stock to make a market-neutral strategy. Peer analysis of DongKook Pharmaceutical could also be used in its relative valuation, which is a method of valuing DongKook Pharmaceutical by comparing valuation metrics with similar companies.
Peers
DongKook Pharmaceutical Related Equities
000660 | SK Hynix | 2.62 | ||||
000270 | Kia Corp | 0.42 | ||||
005387 | Hyundai | 1.15 | ||||
034730 | SK Holdings | 1.34 | ||||
005385 | Hyundai | 1.94 | ||||
005380 | Hyundai | 2.13 | ||||
005490 | POSCO Holdings | 2.40 | ||||
005930 | Samsung Electronics | 2.52 | ||||
005935 | Samsung Electronics | 3.97 |
Complementary Tools for DongKook Stock analysis
When running DongKook Pharmaceutical's price analysis, check to measure DongKook Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DongKook Pharmaceutical is operating at the current time. Most of DongKook Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of DongKook Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DongKook Pharmaceutical's price. Additionally, you may evaluate how the addition of DongKook Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Equity Valuation Check real value of public entities based on technical and fundamental data |